Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 1179 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

1,179 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,179 programs

Clinical programs

Page 14 of 25

  1. TAK-279

    Takeda

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  2. TAK-279-CD-2001

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  3. TAK-279-UC-2001

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  4. TAK-279-VT-2001

    Takeda

    Non-segmental vitiligo

    phase 2 small molecule active

    1 trial

  5. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  6. TAK-280-1501

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  7. TAK-341

    Takeda

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  8. TAK-341-2001

    Takeda

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  9. TAK-360

    Takeda

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  10. TAK-360

    Takeda

    Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  11. TAK-360-2001

    Takeda

    Narcolepsy without Cataplexy (NT2)

    phase 2 other active

    1 trial

  12. TAK-360-2002

    Takeda

    Idiopathic Hypersomnia (IH)

    phase 2 other active

    1 trial

  13. TAK-379

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  14. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  15. TAK-385

    Takeda

    Uterine Fibroids

    phase 2 small molecule completed

    1 trial

  16. TAK-390MR_204

    Takeda

    Symptomatic nonerosive GERD in paediatric subjects aged 2 to 11 years

    phase 2 small molecule active

    1 trial

  17. TAK-390MR_205

    Takeda

    Erosive Esophagitis

    phase 2 small molecule active

    1 trial

  18. TAK-411

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 2 mab active

    1 trial

  19. TAK-442

    Takeda

    Acute Coronary Syndrome

    phase 2 small molecule completed

    1 trial

  20. TAK-442

    Takeda

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  21. TAK-448

    Takeda

    Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  22. TAK-448

    Takeda

    Low Testosterone

    phase 2 small molecule terminated

    1 trial

  23. TAK-500

    Takeda

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  24. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  25. TAK-583

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  26. TAK-653

    Takeda

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  27. TAK-659

    Takeda

    AML

    phase 2 small molecule terminated

    1 trial

  28. TAK-662

    Takeda

    Congenital Protein C Deficiency

    phase 2 small molecule completed

    1 trial

  29. TAK-676-1002

    Takeda

    Solid Neoplasm

    phase 2 small molecule active

    1 trial

  30. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  31. TAK-715 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  32. TAK-755

    Takeda

    Acute Ischemic Stroke

    phase 2 mab active

    1 trial

  33. TAK-755-2001

    Takeda

    Immune-mediated thrombotic thrombocytopenic purpura (iTTP)

    phase 2 small molecule active

    1 trial

  34. TAK-783 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  35. TAK-788

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  36. TAK-788

    Takeda

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  37. TAK-850

    Takeda

    Influenza Prevention

    phase 2 small molecule terminated

    1 trial

  38. TAK-850

    Takeda

    Influenza

    phase 2 small molecule completed

    1 trial

  39. TAK-850

    Takeda

    Influenza Infection

    phase 2 mab completed

    1 trial

  40. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  41. TAK-853

    Takeda

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  42. TAK-906 Maleate

    Takeda

    Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

    phase 2 small molecule completed

    1 trial

  43. TAK-906 Maleate

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  44. TAK-919

    Takeda

    Coronavirus Disease (COVID-19)

    phase 2 mab completed

    1 trial

  45. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  46. TAK-935

    Takeda

    Developmental and/or Epileptic Encephalopathies

    phase 2 small molecule completed

    1 trial

  47. TAK-935

    Takeda

    Epilepsy

    phase 2 small molecule completed

    2 trials

  48. TAK-951

    Takeda

    Postoperative Nausea and Vomiting (PONV)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.